EU/3/20/2395: Orphan designation for the treatment of amyotrophic lateral sclerosis

Celecoxib / Ciprofloxacin


On 6 January 2021 orphan designation EU/3/20/2395 was granted by the European Commission to Morrison & Foerster, Belgium, for celecoxib, ciprofloxacin (also known as PrimeC) for the treatment of amyotrophic lateral sclerosis.

Key facts

Active substance
  • Celecoxib
  • Ciprofloxacin
Intended use
Treatment of amyotrophic lateral sclerosis
Orphan designation status
EU designation number
Date of designation

Ferenc Tracik
Seelengraben 24
9073 Ulm


Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

Date Update
June 2022 The sponsorship was transferred from Morrison & Foerster, Belgium to Ferenc Tracik, Germany in June 2022.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating